Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

Neuro-Oncology

Volumn 11, Issue 3, 2009, Pages 301-310

  Zhou, Qingyu ^a   Gallo, James M ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Antiangiogenic therapy; Combination chemotherapy; Pharmacokinetics; Sunitinib; Temozolomide; Vascular normalization

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 4; SUNITINIB; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; GLIOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STEADY STATE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DRUG INTERACTIONS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INDOLES; MALE; MICE; MICE, NUDE; PYRROLES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649583236     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-088     Document Type: Article

References (47)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123. (Pubitemid 32052502)
2. Senger D, Cairncross JG, Forsyth PA. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J. 2003;9:214-221. (Pubitemid 126820190)
3. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24:1253-1265. (Pubitemid 46622028)
4. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362-372. (Pubitemid 26023356)
5. Wesseling P, van der Laak JA, Link M, Teepen HL, Ruiter DJ. Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol. 1998;29:352-358. (Pubitemid 28231899)
6. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364. (Pubitemid 26272076)
8. Kesisis G, Broxterman H, Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des. 2007;13:2795-2809. (Pubitemid 350130974)
9. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery. 2008;62:31-50. (Pubitemid 351640237)
10. Albini A, Noonan DM, Ferrari N. Molecular pathways for cancer angioprevention. Clin Cancer Res. 2007;13:4320-4325. (Pubitemid 47219694)
11. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116-1119. (Pubitemid 36428215)
12. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337. (Pubitemid 36109749)
13. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in pre-clinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478.
14. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597-3605. (Pubitemid 36857948)
15. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;13:1367-1373.
16. de Boüard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-Oncology. 2007;9:412-423.
17. Goodman VL, Rock eP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367-1373. (Pubitemid 46450424)
18. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18:1282-1283. (Pubitemid 47244377)
19. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27:4255-4257.
20. Helgason HH, Mallo HA, Droogendijk H, et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008;26:152-154.
21. Leenders WP, Küsters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium. 2002;9:83-87. (Pubitemid 35252016)
22. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VeGF. Science. 1999;284:1994-1998. (Pubitemid 29309448)
23. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997;151:1417-1423. (Pubitemid 27479772)
24. Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol. 2001;195:336-342. (Pubitemid 32998359)
25. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VeGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-314. (Pubitemid 30703463)
26. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628. (Pubitemid 32896475)
27. van Kempen LC, Leenders WP. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. Eur J Cell Biol. 2006;85:61-68. (Pubitemid 43137111)
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
29. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942-3950. (Pubitemid 47037602)
30. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008;14:1540-1549.
31. Taghian AG, Suit HD. Animal systems for translational research in radiation oncology. Acta Oncol. 1999;38:829-838.
32. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Path. 2008;18:423-433. (Pubitemid 351782851)
33. Ma J, Li S, Reed K, Guo P, Gallo JM. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther. 2003;305:833-839. (Pubitemid 36617958)
34. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol. 1994;20:121-139. (Pubitemid 24309908)
35. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 2006;12:143-147. (Pubitemid 44719640)
36. Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori. 2007;93:248-256. (Pubitemid 47080010)
37. Payne MJ, Pratap Se, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol. 2005;53:241-252. (Pubitemid 40254921)
38. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491-5498. (Pubitemid 32694932)
39. Oldendorf WH. Blood-brain barrier permeability to drugs. Annu Rev Pharmacol. 1974;14:239-248.
40. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23:682-684. (Pubitemid 11237830)
41. Levin VA. Pharmacokinetics and central nervous system chemotherapy. In: Hellmann K, Carter SK, eds. Fundamentals of Cancer Chemotherapy. New York: McGraw-Hill; 1987:28-40.
42. Thomas F, Rudraraju V, Lockman P, Smith Q. Blood-brain barrier permeability and transport of temozolomide [abstract]. AAPS PharmSci. 2007;1646. Available at http://www.aapsj.org/abstracts/AM-2007/AAPS2007-001646.PDF. Accessed February 5, 2008.
43. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther. 2008;7:71-78.
44. Leenders WP, Küsters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res. 2004;10:6222-6230. (Pubitemid 39287530)
45. Guérin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol. 2008;134:51-57. (Pubitemid 350060684)
46. Schueneman AJ, Himmelfarb e, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63:4009-4016. (Pubitemid 36917920)
47. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585-2597. (Pubitemid 30482092)